[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-lymphoma-non-hodgkin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-lymphoma-non-hodgkin":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100574197","phase-2-preventing-of-gvhd-with-post-transplantation-cyclophosphamide-abatacept-vedolizumab-and-ruxolitinib-at-children-and-young-adults-with-hemoblastosis-100574197",false,"NCT06756152","Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor","Inclusion Criteria:\n\n1\\. Patients under the age of 21 years with following diseases:\n\n* acute lymphoblastic,\n* myeloblastic,\n* biphenotypic,\n* bilinear leukemia,\n* malignant lymphoma,\n* myelodysplastic syndrome,\n\nExclusion Criteria:\n\nAge over 21 years\n\n* Patients with ALL outside clinical and hematological remission\n* Clinical status:\n\n  * Lansky\u002FKarnowski index \\\u003C70% (supplement No.1)\n  * Heart function: left ventricular ejection fraction \\\u003C40% according to ultrasound of the heart1\n  * Kidney function: clearance of endogenous creatinine \\\u003C 70 ml \u002F min\n  * Liver function: total bilirubin, ALT, AST, ALP \\> 2 norms\n  * Lung function: lung capacity \\\u003C50%, for children who cannot carry out of respiratory function - oxygen saturation during pulse oximetry \\\u003C92%\n* Uncontrolled viral, fungal or bacterial infection.\n* Mental illness of the patient or caregivers, making it impossible to realize the essence of the study and compromising compliance with medical appointments and sanitary and hygienic regime 1 These patients may receive treatment according to the protocol, but the results will be evaluated separately","ALL","1 Day","21 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan\u002FTBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors",[28,29,30,31,32,33],"Biphenotypic Acute Leukemia","Acute Lymphoblastic Leukemia","Myeloblastic Leukemia","Bilinear Leukemia","Malignant Lymphoma, Non-Hodgkin","Myelodysplastic Syndrome",[35,36,37,38,16,39],"Hematopoetic stem cell transplantation","posttransplant cyclophosphamide","vedolizumab","hematoblastosis","AML","RECRUITING","2024-12-24",{"date":43,"type":44},"2025-01-01","ACTUAL",{"date":46,"type":44},"2024-07-10",{"date":48,"type":21},"2026-10-10",{"name":50,"class":51},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","OTHER"]